Vibration Analysis for Pharmaceutical Manufacturing

equipment modifications require change control and validation impact assessments; maintenance activities generate deviation investigations when they affect batch quality. In this environment, equipment failures cause batch deviations, product holds, FDA 483 observations, and consent decree risk. Our spectral vibration measurement program specifically targets HVAC air handling units, lyophilizers, tablet presses, centrifuges, clean utility systems (WFI, clean steam), and packaging lines — the assets where early detection has the greatest impact on batch success rate and deviation closure time. We also account for strict change control requirements, adapting our measurement approach to maintain data quality despite these operating conditions.

Yes. Pharmaceutical facilities must comply with FDA 21 CFR Parts 210/211 cGMP, EU Annex 15 qualification, and ISPE GAMP 5 for computerized systems. Our spectral vibration measurement program generates the condition documentation needed for cgmp-compliant maintenance documentation with audit trail, equipment qualification records, and calibration traceability. Beyond compliance, the condition data drives measurable improvements in batch success rate and deviation closure time by converting unplanned failures into scheduled repairs. Most pharmaceutical clients see meaningful reductions in batch deviations within the first 12 months of program implementation.

Pharmaceutical operations bring three things to the Vibration Analysis program that aren't there in general industry. The operating environment is harder (GMP validation, cleanroom equipment, batch traceability). The regulatory framework adds documentation requirements (FDA cGMP, EU Annex 15, ICH Q7). And the cost of failure is higher — typical unplanned downtime runs $10K-$80K/hour with batch loss risk. A Vibration Analysis program built for Pharmaceutical accounts for all three: tighter intervals on the equipment most exposed to sanitary pump reliability, clean utility integrity, batch traceability, audit-ready reporting templates, and faster response times on flagged developing faults.

Most of it, yes. Vibration Analysis measurements at overall velocity per ISO 10816-3, plus envelope spectrum 1-10 kHz are non-intrusive — readings happen at the bearing housing or terminal box without interrupting the equipment. The exceptions are deep diagnostic work that requires de-energization or process isolation, which most Pharmaceutical facilities batch into existing maintenance windows. Routine Vibration Analysis rounds disrupt nothing.